SEC Form 4 · accession 0001179110-17-002807
AbbVie Inc. · ABBV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry O Gosebruch
Officer — Chief Strategy Officer
Period of report
Feb 16, 2017
Accepted (ET)
Feb 21, 2017 · 5:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001551152
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, $0.01 par valueF1 | Feb 16, 2017 | A | 31,196 | $0.00 | A | 108,375 | D | |
| Common stock, $0.01 par valueF2 | Feb 16, 2017 | A | 14,035 | $0.00 | A | 122,410 | D | |
| Common stock, $0.01 par valueF3 | holding | — | — | — | 1,019 | I | Profit sharing trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F4 | $61.36 | Feb 16, 2017 | A | 78,340 | A | Feb 16, 2018 | Feb 15, 2027 | Common stock | 78,340 | 78,340 | D |
Explanation of responses
- F1Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on adjusted earnings per share and relative total shareholder return measures. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017.
- F2Represents shares of AbbVie common stock issued under a performance-vested restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2017.
- F3Balance in AbbVie Savings Program as of February 16, 2017.
- F4Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.The option becomes exercisable in annual increments of 26,114 on 02/16/2018, 26,113 on 02/16/2019, and 26,113 on 02/16/2020.